The QualityStocks Daily Monday, December 3rd, 2018

Today's Top 3 StockMarketWatch

StockMarketWatch (AETI) +169.93%

MarketClub Analysis (TSRO) +57.96%

StocksToBuyNow (ASCK) +55.73%

The QualityStocks Daily Stock List

Gold Reserve, Inc. (GDRZF)

Savvy Trader Resource, 4-Traders, The Street, Stockhouse, OTC Markets, MarketWatch, Otc. Watch, The Otc Reporter, Barchart, Business Wire, Equities, InvestorsHub, Investors Hangout, Super Stock Screener, GuruFocus, and Morningstar reported previously on Gold Reserve, Inc. (GDRZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Gold Reserve, Inc. acquires, explores, and develops mining projects. It has a history in mining dating back to 1956 and established for the purpose of acquiring, exploring, and developing mining properties and placing them into production. An exploration stage enterprise, Gold Reserve is based in Spokane, Washington and the Company’s shares trade on the OTC Markets Group’s OTCQX.

Gold Reserve`s aim is to successfully develop proven and probable reserves through making selective property and/or corporate acquisitions. In 1992, Gold Reserve acquired and began developing what is now known as the Brisas gold and copper project, situated in the historic Km 88 mining district of the State of Bolivar in southeastern Venezuela. The Brisas deposit contains ore reserves of 10.2 million ounces of gold and 1.4 billion pounds of copper.

On March 1, 2016, Gold Reserve completed the acquisition of certain wholly-owned mining claims called the LMS Gold Project (LMS Property), together with certain personal property for $350,000, pursuant to a Purchase and Sale Agreement with Raven Gold Alaska, Inc., a wholly-owned subsidiary of Corvus Gold, Inc. The LMS Property remains at an early stage of exploration. It is not material to Gold Reserve.

Gold Reserve announced earlier this year that the mixed company Empresa Mixta Ecosocialista Siembra Minera S.A. (SM), owned 45 percent by Gold Reserve and 55 percent by the Bolivarian Republic of Venezuela, received the Permit to Effect for the Siembra Minera Gold Copper Project (SM Project) from the Venezuelan Ministry of the Environment. The Permit to Effect will allow site clearing, construction of a temporary camp and warehouse facilities, drilling of dewatering and development drill holes, construction of access roads on the property, and opening of the quarry for construction aggregates.

Last week, Gold Reserve announced that for the nine months ended September 30, 2018 it had Net Earnings After Tax of US$67.8 million or US$0.68 per share versus US$81.8 million or US$0.89 per share in the same period of 2017. For the three months ended September 30, 2018 Gold Reserve had Net Earnings After Tax of US$3.7 million or US$0.04 per share versus US$34.3 million or US$0.36 per share in the same period of last year.

Gold Reserve completed a positive NI-43-101 compliant Preliminary Economic Assessment (PEA) on the Siembra Minera project this year and completed preliminary design and cost estimates and related tailings dam facilities for the Small Plant. It also initiated activities associated with the preparation of a Venezuela Environment Impact Statement (VEIS) and International Environmental and Social Impact Assessment (IESIA), collected a surface saprolite material sample for transport to the U.S. for metallurgical testing and acquired the permit to effect the environment for the Siembra Minera Project (Permit to Effect) from the Venezuelan Ministry of the Environment.

Gold Reserve, Inc. (GDRZF), closed Monday's trading session at $2.3966, even for the day, on 4 volume with 1 trade. The average volume for the last 3 months is 26,641 and the stock's 52-week low/high is $1.84/$3.51.


Cardax, Inc. (CDXI)

Zacks, StreetInsider, and InvestorsHub reported on Cardax, Inc. (CDXI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cardax, Inc. is a development stage Life Sciences Company listed on the OTC Markets. It dedicates primarily all its efforts to developing consumer health and pharmaceutical products, which it believes will provide many of the anti-inflammatory benefits of steroids or NSAIDS through targeting many of the same inflammatory pathways and mediators, but with exceptional safety profiles. Cardax has its corporate office in Honolulu, Hawaii.

The Company is preparing proprietary nature-identical products and related derivatives via total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated. This includes, but is not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease.

Cardax’s initial primary focus is its astaxanthin technologies. Astaxanthin is a strong and safe, naturally occurring, anti-inflammatory and anti-oxidant without the adverse side effects characteristic of anti-inflammatory treatments using steroids or NSAIDS (including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding). The safety and efficacy of Cardax’s product candidates have not been directly evaluated in clinical trials or confirmed by the Food and Drug Administration (FDA).

Cardax’s ZanthoSyn® is its first product to help consumers safely address their inflammatory health. Cardax says that ZanthoSyn® is a physician recommended, anti-inflammatory supplement for health and longevity that features astaxanthin with optimal absorption and purity. ZanthoSyn® contains astaxanthin, which is Generally Recognized as Safe (GRAS) according to FDA regulations.

Cardax announced in October of 2017 that it entered into a mutual exclusivity agreement with General Nutrition Corporation (GNC) for ZanthoSyn. The exclusivity agreement builds on Cardax’s earlier announced national rollout of ZanthoSyn across GNC's more than 3,200 United States corporate stores.

It now designates GNC as the exclusive "brick-and-mortar" retailer of ZanthoSyn in the United States. The exclusivity agreement covers the use of ZanthoSyn as a human dietary supplement, with an initial term of two years and provides for automatic renewals. GNC is the foremost specialty retailer of health, wellness, and performance products.

In February, Cardax announced that it signed a Purchase Agreement with Health Elite Club Limited (HECL) of Hong Kong. This Agreement is for the distribution of ZanthoSyn® in China, Hong Kong, Macau, and Taiwan (the Territories). ZanthoSyn® will be distributed in the Territories under HECL's house brand, Puerfons. All packaging and marketing materials will feature the ZanthoSyn® brand.

Recently, Cardax announced its results for the year ended December 31, 2017, its first full year of sales. Revenues from ZanthoSyn® increased from $35,258 in 2016 (following product launch in August 2016) to $610,323 for the full year of 2017. Revenues of $114,235 for Q4 2017 were up almost 5 times from 2016 Q4 Revenues of $24,098.

Cardax, Inc. (CDXI), closed Monday's trading session at $0.215, up 2.38%, on 34,800 volume with 7 trades. The average volume for the last 3 months is 20,806 and the stock's 52-week low/high is $0.07/$0.439.


Sun Pacific Holding Corp. (SNPW)

Zacks, Marketwired, and reported on Sun Pacific Holding Corp. (SNPW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sun Pacific Holding Corp. works to protect the environment with smart green technology. The Company’s subsidiaries include Sun Pacific Power Corp, Street Smart Outdoor Corp, Bella Electrical LLC, National Mechanical Corp, and Sun Pacific Security Corp. Sun Pacific Holding has its corporate headquarters in Manalapan, New Jersey. The Company’s shares trade on the OTC Markets Group’s OTCQB.

In 2016, Company subsidiary, Sun Pacific Power, obtained final design of its Smart Solar Bus Shelter. It commenced deploying it in Sayreville and Howell, New Jersey. The Smart Solar Bus Shelter provides LED lighting for increased visibility and security and also other technological additions not formerly available.

Sun Pacific Power builds next generation solar panels and lighting products made chiefly in the United States. Sun Pacific Power has eight global manufacturing and assembly locations. This includes five in the USA.

Sun Pacific Holding’s subsidiary, Sun Pacific Security, offers customers the latest in security automation systems. This subsidiary enables one to view secure, live and recorded video of their property at any time on their computer, smartphone or tablet.

Recently, Sun Pacific Holding announced that Street Smart Outdoor, its wholly-owned subsidiary, contracted with the State of Rhode Island Transportation Authority. Mr. Nicholas Campanella, Sun Pacific Holding’s Chief Executive Officer, said, "Street Smart Outdoor Corp. has formally signed a ten year contract with the state of Rhode Island Transportation Authority to manage and sell advertising space on over 700 bus shelter faces which serve the local residents of Rhode Island."

In late November, Sun Pacific Holding announced the start of Sun Pacific Power’s contract with the city of Tallahassee. This involves the start of the installation and maintenance of Solar Powered Bus Shelters and Transit Amenities at hundreds of locations throughout Tallahassee, Florida.

The contract is with Star Metro. Star is the transportation authority in the State of Florida’s capital city Tallahassee. Sun Pacific is to provide street furniture and other transit amenities. This includes its solar powered Smart Shelters and benches throughout the city of Tallahassee, fixed routes on the campuses of Florida State University and Florida A&M University, and its unincorporated areas.

This week, Sun Pacific Holding announced its partnership with CrowdfundX, which is a FinTech marketing firm and developer of Dara, a semi-autonomous machine, which empowers public and private companies to streamline retail investor acquisition.

Sun Pacific Holding has engaged CrowdfundX in a 6-month contract. CrowdfundX takes advantage of a combination of Artificial Intelligence (AI) and digital marketing to help issuers acquire retail investors and shareholders at scale.

Sun Pacific Holding Corp. (SNPW), closed Monday's trading session at $0.015755, up 12.54%, on 562,400 volume with 16 trades. The average volume for the last 3 months is 121,550 and the stock's 52-week low/high is $0.0126/$0.8199.


Valeritas Holdings, Inc. (VLRX)

StockTwits, Zacks, Street Insider, Barchart, 4-Traders, Simply Wall St, Stockwatch, InvestorsHub, The Street, and Investor Network reported on Valeritas Holdings, Inc. (VLRX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Valeritas Holdings, Inc. is a commercial-stage medical technology company. It offers patients with type 2 diabetes the V-Go® Wearable Insulin Delivery device. This is a simple, all-in-one insulin delivery option. The V-Go® Wearable Insulin Delivery device is worn like a patch. It can eliminate the need for taking numerous daily shots.

Listed on the NasdaqCM, Valeritas Holdings is headquartered in Bridgewater, New Jersey. The Company operates its research and development (R&D) functions in Marlborough, Massachusetts.

Valeritas Holdings’ flagship product, V-Go® Wearable Insulin Delivery device, is a wearable, basal-bolus insulin delivery device for patients with type 2 diabetes. It enables patients to administer a continuous preset basal rate of insulin over 24 hours.

In addition, it provides discreet on-demand bolus dosing at mealtimes. The V-Go® Wearable Insulin Delivery device is the only basal-bolus insulin delivery device on the market today purposely designed keeping in mind the needs of type 2 diabetes patients.

Last week, Valeritas Holdings announced that it signed an exclusive distribution agreement with AMSL Diabetes and NZMS Diabetes. This distribution agreement is for the commercialization of its V-Go® Wearable Insulin Delivery device in Australia and New Zealand. With this agreement, AMSL Diabetes and NZMS Diabetes will have the rights to promote, market, as well as sell the V-Go to diabetes clinics and patients in Australia and New Zealand.

Valeritas Holdings will retain responsibility for product development, regulatory approval, quality management, and manufacturing.  AMSL Diabetes and NZMS Diabetes will be responsible for sales, marketing, customer support and distribution activities in Australia and New Zealand.

In addition, last week, Valeritas Holdings announced it entered into an agreement with Glooko, a leader in diabetes data management. Under the agreement, Valeritas will provide future V-Go SIM (Simple Insulin Management) users with Glooko’s cloud-based mobile and web diabetes data management platform to help track and analyze their diabetes care plan. As well, users can share their data with their providers.

V-Go SIM is a new, long-lasting accessory. It will snap onto the Company’s flagship product, V-Go® Wearable Insulin Delivery device. The design of it is to provide one-way Bluetooth communication from the V-Go SIM to a patient’s smart device.

The V-Go SIM's onboard electronics will provide information concerning V-Go’s use and wirelessly transmit the data through a V-Go SIM application (app) on a mobile device. The V-Go SIM is investigational. The expectation is that it will not be available for full commercial use in the United States until the first half of 2019.

Valeritas Holdings, Inc. (VLRX), closed Monday's trading session at $0.3898, up 7.71%, on 1,785,767 volume with 3,250 trades. The average volume for the last 3 months is 1,151,420 and the stock's 52-week low/high is $0.35/$4.738.


H/Cell Energy Corporation (HCCC)

MarketWatch, OTC Markets, Marketbeat, Stockopedia, 4-Traders, Wall Street Analyzer, Trading View, Oil & Gas 360, and Market Exclusive reported on H/Cell Energy Corporation (HCCC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

H/Cell Energy Corporation is a systems integrator headquartered in Flemington, New Jersey. The Company centers on the design and implementation of clean energy solutions. These include solar, battery technology, and hydrogen energy systems. The Company serves the residential, commercial, and government sectors. H/Cell Energy’s shares trade on the OTC Markets Group’s OTCQB.

Furthermore, by way of its Pride Group subsidiary, H/Cell Energy provides security systems integration. The Pride Group is headquartered in Australia.

H/Cell Energy manages all projects. The Company has developed and implemented a hydrogen energy system utilized to totally power a residence or commercial property with clean energy. This is so the property can run independent of the utility grid as well as provide energy to the utility grid for monetary credits. The innovative system utilizes renewable energy as its source for hydrogen production.

H/Cell Energy named the hydrogen energy system the HC-1. This is a system consisting of solar panels, inverters, batteries, a hydrogen generator, a fuel cell and a hydrogen storage tank.

The design of each HC-1 system is to accommodate the electrical loads for an end user. The HC-1 system is scalable. It can be configured to meet any kilowatt hour (kWh) demands.

The Company has two completed projects to date. One is the De Tiberge Property, in Pennington, New Jersey. The other is the Strizki Property in Hopewell, New Jersey, which was the first hydrogen energy system installed in North America.

Earlier this month, H/Cell Energy announced that effective February 1, 2018, the Company acquired PVBJ, Inc. of Downingtown, Pennsylvania for $1 million of H/Cell Energy stock and $221,800 in cash. PVBJ is well recognized for the design, installation, maintenance and emergency service of environmental systems in commercial and residential markets.

Moreover, PVBJ is currently expanding into renewable energy systems. Mr. Paul Benis, PVBJ’s President, will remain in his position and became an Executive Vice President of H/Cell Energy.

Mr. Andrew Hidalgo, Chief Executive Officer of H/Cell Energy, said, “Our acquisition strategy focuses on companies that are profitable, have a significant customer base that can be introduced to our technology and have a talented group of technicians that can be trained to install our systems. PVBJ meets all these requirements. They have been a very successful company and we look forward to assimilating their organization into HCCC.”

H/Cell Energy Corporation (HCCC), closed Monday's trading session at $0.75, up 44.04%, on 10,090 volume with 21 trades. The average volume for the last 3 months is 166 and the stock's 52-week low/high is $0.521/$3.25.


U.S. Stem Cell, Inc. (USRM)

MarketWatch, TradingView, InvestorsHub, and Money Morning reported on U.S. Stem Cell, Inc. (USRM), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

U.S. Stem Cell, Inc. is a developing enterprise in the regenerative medicine/cellular therapy industry. The Company is a developer of novel autologous cell therapies, and a provider of physician based stem cell therapies to human and animal patients. U.S. Stem Cell has three operating divisions: US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic.

Founded in 1999, U.S. Stem Cell is based in Sunrise, Florida. The Company formerly went by the name Bioheart, Inc. It changed its name to U.S. Stem Cell, Inc. in October of 2015.

U.S. Stem Cell’s emphasis is on the discovery, development, and commercialization of cell based therapeutics that prevent, treat, or cure disease through repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.

Its lead product candidate is MyoCell®. This is a muscle stem cell therapy intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

The Company’s business includes the development of proprietary cell therapy products and revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.

MyoCell SDF-1 has received approval from the Food and Drug Administration (FDA) to commence human clinical trials. The intention of MyoCell SDF-1 is to be an improvement to MyoCell. Regarding its AdipoCell product, U.S. Stem Cell has applied to the FDA to start trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.

This past March, U.S. Stem Cell announced that it developed a strategic alliance with Advanced Stem Cell Rx (ASC) including the development of autologous stem cell treatment centers throughout the U.S. ASC is a U.S. based provider of regenerative medicine programs.

ASC is commercializing many of the proprietary treatments developed by U.S. Stem Cell. ASC is currently implementing turnkey programs into qualified practices throughout the U.S. ASC has contracted with practices in greater than 20 U.S. States.

U.S. Stem Cell has an aggressive plan to expand an additional 12 stem cell treatment centers and clinics in the U.S. The Company is investing and focusing on its in-clinic therapies for patients.

Last week, U.S. Stem Cell announced the publication of a new study, which demonstrates the safety of autologous stem cell therapy in degenerative diseases and injuries. The study, entitled "Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction," is the largest safety trial so far that used stem cells from fat.

The study was published in the Journal of Clinical Medicine Research and co-authored by U.S. Stem Cell Chief Science Officer Kristin Comella, PhD, and Michelle Parlo, PA, Rosemary Daly, DO, Vincent Depasquale, DC, Eric Edgerton, DC, Patrick Mallory, DO, Roy Schmidt, MD, Walter P. Drake, PhD.

U.S. Stem Cell, Inc. (USRM), closed Monday's trading session at $0.0221, up 7.80%, on 223,265 volume with 19 trades. The average volume for the last 3 months is 1,384,025 and the stock's 52-week low/high is $0.0195/$0.0879.


HedgePath Pharmaceuticals, Inc. (HPPI)

Infront Analytics, Morningstar, MarketWatch, InvestorsHub, BUYINS.NET, Stockhouse, Simply Wall St, 4-Traders, Dividend Investor, and Wallet Investor reported previously on HedgePath Pharmaceuticals, Inc. (HPPI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company listed on the OTC Markets` OTCQB. The Company discovers, develops, and plans to commercialize front-line therapeutics for patients with cancer. It is looking to repurpose the Food and Drug Administration (FDA) approved antifungal pharmaceutical itraconazole as a potential treatment for cancer. HedgePath Pharmaceuticals is based in Tampa, Florida.

The Company is the exclusive U.S. licensee of a patented formulation of itraconazole, called SUBA-Itraconazole. Clinical studies have shown it to have more bioavailability than generic itraconazole. The Hedgehog signaling pathway is a major regulator of cellular processes in vertebrates. This includes cell differentiation, tissue polarity, and cell proliferation.

HedgePath Pharmaceuticals believes (based on published research) that inhibiting the Hedgehog pathway could delay or possibly prevent the development of certain cancers in humans. Taking advantage of research undertaken by key investigators in the field, the Company’s plan is to explore the effectiveness of SUBA-Itraconazole as an anti-cancer agent and to pursue its potential commercialization.

The design of “SUBA technology” (which stands for “Super Bioavailability”) is to improve the bioavailability of orally administered drugs that are poorly soluble. SUBA-Itraconazole is a patented formulation developed by Mayne Pharma. It has improved absorption and considerably reduced variability versus generic itraconazole.

HedgePath Pharmaceuticals announced this past August that the U.S. Food and Drug Administration (FDA) confirmed the Company's current clinical and regulatory pathway related to HedgePath’s SUBA™-Itraconazole as a treatment for Basal Cell Carcinoma (BCC) in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS, or Gorlin Syndrome). The FDA's positive feedback was received at HedgePath’s previously announced July 23, 2018 Type-C Meeting with the FDA. It was confirmed in minutes of the meeting received by HedgePath from the FDA.

Recently, HedgePath Pharmaceuticals announced it gained additional clarity concerning its clinical program and the anticipated timing for filing of its New Drug Application (NDA) for SUBA™-Itraconazole as a treatment for Basal Cell Carcinoma in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS) based on meeting minutes received by the Company from the FDA relating to its face-to-face meeting with the FDA on September 25, 2018.

Mr. Nicholas J. Virca, HedgePath Pharmaceuticals, Inc.`s (HPPI's) President and Chief Executive Officer, stated, "We are pleased with the outcome of this meeting with FDA as we have gained important additional clarity on what is required for our SUBA BCCNS NDA. The consequence of FDA requiring the completion of the ISS module is that HPPI will require more time than we previously anticipated to submit our NDA, resulting in a revised anticipated NDA submission date of sometime in the first quarter of 2019. We are currently in the process of performing the requested updates, which we believe will enhance our data package."    

HedgePath Pharmaceuticals, Inc. (HPPI), closed Monday's trading session at $0.13, down 18.75%, on 31,642 volume with 9 trades. The average volume for the last 3 months is 19,558 and the stock's 52-week low/high is $0.1545/$0.375.


Hummingbird Resources PLC (HUMRF)

Stockhouse, Mining Stock Valuator, 4-Traders, Wallet Investor, Barchart, Malibu Report, MarketWatch, Wallstreet Online, and YCharts reported earlier on Hummingbird Resources PLC (HUMRF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Established in 2005, Hummingbird Resources PLC is an emerging + 100,000 oz gold producer. The Company has successfully built and commissioned its high-grade Yanfolila Gold Project in Mali. Its team has 124 years experience in Africa on 61 projects, as well as 143 years operational experience. The Company’s goal is to become a significant mid-tier producer. Hummingbird Resources is headquartered in London, England.

Hummingbird Resources also has a 34 percent stake in Cora Gold. Cora has its Sanankoro gold discovery: potential for a 1Moz+ standalone mine development. Stage 1 drilling is complete at the Sanankoro gold discovery with new targets identified and very encouraging high-grade gold intercepts. 

Hummingbird Resources (since its IPO (Initial Public Offering)) has substantially increased its gloabl resource inventory from an initial 0.8Moz to 6.4Moz throughout two countries, Mali and Liberia. It at first concentrated most of its resources on the Dugbe Gold Project in Liberia following the low-cost acquisition of Gold Fields’ gold assets in Mali in 2014. The Dugbe Gold Project is the largest known gold deposit in the country.

The Company has subsequently refocused its attention on the high grade Yanfolila Gold Project. However, the Dugbe Gold Project remains a vital component of its portfolio. In April 2013, Hummingbird Resources published a positive PEA (Preliminary Economic Assessment). The Company is now making progress with its Detailed Feasibility Study (FS).

The Yanfolila Gold Mine is in southern Mali. Yanfolila is a low cost, high grade open pit mining operation. It poured first gold in December 2017. The 2018 Exploration Program for the Yanfolila Gold Mine is targeting +50,000 m drilling at 6 deposits to convert an additional 400,000 ozs to Reserves. The Deposit is open on strike and at depth.

Concerning Yanfolila, the 2018 guidance is 105 - 115 KOZ. Expansion is from the Gonka Deposit. There is the potential to increase production, and also substantial life of mine extension potential.

Last week, Hummingbird Resources announced a follow up to its announcement on October 25, 2018 concerning a pit stability issue after a significantly heavier than normal wet season. A comprehensive analysis surrounding the required remediation work on the western wall of the Komana East pit at the Yanfolila Gold Mine was completed and remediation work has now started. Production from Yanfolila has continued throughout this period. It will continue during the remediation work.

The Company’s 2018 full year production guidance has been adjusted to 87,000 – 92,000 oz. Its 2019 full year production at Yanfolila is to reach between 110,000 – 125,000 oz with a targeted AISC of US$800/oz.

Hummingbird Resources PLC (HUMRF), closed Monday's trading session at $0.24, down 3.92%, on 5,000 volume with 1 trade. The average volume for the last 3 months is 8,773 and the stock's 52-week low/high is $0.2145/$0.535.


OriginClear, Inc. (OCLN)

MarketWatch reported on OriginClear, Inc. (OCLN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, OriginClear, Inc. is a leading provider of water treatment solutions. The Company is also the developer of an inventive water cleanup technology. By way of its wholly-owned subsidiaries, OriginClear provides systems and services to treat water in a broad assortment of industries. These include municipal, pharmaceutical, semiconductors, industrial, and oil & gas. The Company has its wholly-owned subsidiary, Progressive Water Treatment (PWT) of Dallas, Texas. OriginClear has its head office in Los Angeles, California.

OriginClear invented Electro Water Separation™. This is a pioneering high-speed water cleanup technology employing multi-stage electrolysis, which OriginClear licenses globally to water treatment equipment manufacturers.

Electro Water Separation™ (EWS) is a highly scalable, continuous process. It uses electricity in small, programmed doses to gather up oils and suspended solids. Moreover, through Advanced Oxidation or AOx, it removes fine, micron-sized suspended solids, and dissolved contaminants, including ammonia.

OriginClear’s mission is to develop Electro Water Separation™ with Advanced Oxidation™ (EWS:AOx™) and accomplish its full recognition as an international industry standard in treating increasingly complex wastewater treatment challenges.

OriginClear entered into a Master Research Agreement with Florida Atlantic University (FAU) in Boca Raton, Florida. The Agreement establishes a cooperative framework for further scientific research and validation projects regarding the Company’s technology, Electro Water Separation with Advanced Oxidation (EWS:AOx), when applied to landfill leachate treatment.

This past October, OriginClear announced that its Asian subsidiary manufactured the Company's first standalone commercial system. This is a compact, full-duty commercial system that utilizes OriginClear's Advanced Oxidation Process, AOx™, to remove ammonia from high-salinity effluent from an electrode-plating facility. OriginClear deploys AOx by itself, when water is already free of suspended solids.

OriginClear Hong Kong is also manufacturing a lab-scale unit for a new licensee in Brazil. It recently built and delivered three like units for licensees in Spain, India and Thailand, and a larger-capacity research and development unit for a European project.

Last month, OriginClear announced a preliminary agreement with the National Superior Engineering School (ENSIL-ENSCI) of France's University of Limoges, to validate OriginClear's innovative process, Electro Water Separation with Advanced Oxidation™ (EWS:AOx™), for extremely challenging water treatment problems. The intellectual property (IP) and knowledge resulting from this collaboration will remain with OriginClear. This agreement followed OriginClear Technologies President Jean-Louis "JL" Kindler's presentation at the International IWA Conference in nearby Nantes.

OriginClear, Inc. (OCLN), closed Monday's trading session at $0.0015, up 7.14%, on 7,724,706 volume with 85 trades. The average volume for the last 3 months is 28,956,298 and the stock's 52-week low/high is $0.0011/$0.05.


Alpine 4 Technologies Ltd. (ALPP)

Stockhouse, TradingView, OTC Markets, InvestorsHub, and MarketWatch reported on Alpine 4 Technologies Ltd. (ALPP), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Established in 2014, Alpine 4 Technologies Ltd. is a technology and manufacturing holding enterprise. The Company has business-related endeavors in Automotive Technologies, Electronics Manufacturing, Software and Data Technologies. Alpine 4 Technologies is headquartered in Phoenix, Arizona. The Company lists on the OTC Markets’ OTCQB.

The Company previously went by the name Alpine 4 Automotive Technologies Ltd. It changed its name to Alpine 4 Technologies Ltd. in June of 2015.

Alpine 4’s emphasis is on how the adaptation of new technologies, even in brick and mortar businesses, can propel innovation. The core of its acquisition strategy is its focus on existing smaller middle market operating companies’ with revenues of $5 to $50 million.

The design of Alpine 4 Technologies is to allow its subsidiaries room to develop their own identities and synergistically prosper from inter-company resources and collaboration. Alpine 4 will own controlling interest in every subsidiary. In addition, it will have direct control over planning and management.

Concerning Alpine 4’s subsidiaries and product groups, these include 6th Sense Auto; BrakeActive™; Quality Circuit Assembly; and Venture West Energy Services. 6th Sense Auto is an automotive technology division of Alpine 4 Technologies. This division provides a distinct and strong advantage to management, sales, finance and service departments at automotive dealerships.

BrakeActive™ is a safety device. It improves a vehicle’s third brake lights ability to substantially lessen or prevent a rear end collision by up to 40 percent. Alpine 4’s Quality Circuit Assembly subsidiary provides electronic contract manufacturing solutions delivered to its customers by way of strategic business partnerships. Furthermore, Venture West Energy Services focuses on supporting the oil and gas industry in Texas, Oklahoma, and Arkansas.

This past November, Alpine 4 Technologies' subsidiary, Quality Circuit Assembly, Inc. (QCA), announced that Lattice Incorporated transferred the redesign and production of its unique NetVisit™ Video Visitation and CellMate® mobile phone system to QCA. This production agreement is worth an estimated $2.3 million dollars per annum for QCA.

Alpine 4 Technologies owns QCA. Alpine 4 earlier announced the expansion of its corporate portfolio by signing a Letter of Intent (LOI) to acquire all outstanding securities of Lattice Incorporated.

Moreover, in November, Alpine 4 Technologies announced that its subsidiary, ALTIA, reached an agreement with Go Imports of Gilbert, Arizona to use their 6th Sense Auto platform for inventory management, customer retention, and resale as an aftermarket connected car product.

6th Sense Auto is designed for the modern "connected car". This subsidiary’s dedication is to helping large dealerships improve their inventory management, engine diagnostics, service maintenance, and personalized customer support via wireless cloud-based software.

This week, Alpine 4 Technologies' subsidiary, Quality Circuit Assembly (QCA), announced that it acquired three new electric vehicle customers in Q4 of 2017. With the addition of these customers, QCA believes that it will be better able to meet its revenue growth plans for this year.

Alpine 4 Technologies Ltd. (ALPP), closed Monday's trading session at $0.071, up 1.43%, on 2,000 volume with 1 trade. The average volume for the last 3 months is 17,162 and the stock's 52-week low/high is $0.0502/$0.3971.


Artemis Therapeutics, Inc. (ATMS)

NetworkNewsWire, Stock Digest, Zacks, Wallmine, OTC Markets, Penny Stock Tweets, 4-Traders, YCharts, Stockhouse, InvestorsHub,, Simply Wall St, and Financial Content reported earlier on Artemis Therapeutics, Inc. (ATMS), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Artemis Therapeutics, Inc. focuses on the development of new therapies for the treatment and prevention of severe and life-threatening infectious diseases. The Company’s lead product candidate is Artemisone. This is an innovative, synthetic artemisinin derivative with potent anti-viral and anti-parasitic properties.  A clinical-stage biopharmaceutical company, Artemis Therapeutics has its corporate office in New York, New York. The Company lists on the OTCQB.

Artemisone is a best-in-class artemisinin. It has been studied in a Phase 2 clinical trial for the treatment of malaria (p. falciparum). Artemis Therapeutics has licensed pre-clinical data from Hadasit Medical Research Services and Development Ltd. in HCMV and clinical data from Hong Kong University of Science and Technology R and D Corporation Limited (RDC) in the treatment of Malaria.

Artemisinin and its derivatives, including artesunate, artemether, arteeter and dihydro-atemisinin (DHA), have for many years been the basis of treatment of uncomplicated p. falciparum malaria. Phase II clinical data has shown Artemisone to be an effective treatment for p. falciparum malaria infection when dosed over a 2-day or 3-day course, similar to or shorter than other available malaria treatments.

Artemisone is currently undergoing in vitro evaluation for its activity against human cytomegalovirus (CMV). This includes transplant CMV and congenital CMV. In June 2018, the Company announced that new data on its lead product candidate Artemisone shows it is a potent inhibitor of human cytomegalovirus (HCMV) replication in preclinical assays.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Artemisone for the treatment of malaria. The Company is now qualified to receive considerable benefits via its orphan drug development program. This includes more frequent FDA interactions, protocol assistance, and tax credits for clinical research expenses.

Artemis Therapeutics announced earlier in 2018 that data on its lead product candidate Artemisone were published in two separate articles in the journal Antimicrobial Agents and Chemotherapy.  The studies indicate that Artemisone in a preclinical setting is a potent inhibitor of human cytomegalovirus (HCMV) replication and the transmissible stages of malaria.

Human cytomegalovirus (CMV) is a common virus related to the viruses that cause chickenpox, herpes simplex, as well as mononucleosis. CMV is transmitted through bodily fluids. Almost half of all Americans are infected by the age of six. In people over age 80, prevalence reaches 90 percent. The virus normally causes no symptoms. It remains latent in the body following infection. However, it may “reactivate” many years later, leading to serious health issues. Artemis Therapeutics` lead product candidate, Artemisone, is undergoing development as a best-in-class treatment for malaria and first-in-class treatment for CMV.

Artemis Therapeutics, Inc. (ATMS), closed Monday's trading session at $0.2601, down 61.75%, on 975 volume with 1 trade. The average volume for the last 3 months is 280 and the stock's 52-week low/high is $0.2601/$1.70.


BioVie, Inc. (BIVI)

Penny Stock Tweets, Investor Place, Wallmine, Wealth Insider Alert, InvestorsHub, Morningstar, YCharts, EuroInvestor, MarketWatch, and Simply Wall St reported previously on BioVie, Inc. (BIVI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. centers on the discovery, development, as well as commercialization of innovative drug therapies for liver disease. Currently, the clinical-stage Company is concentrating on commercializing BIV201. This is a novel approach to the treatment of ascites because of chronic liver cirrhosis. BioVie is based in Beverly, Massachusetts and the Company lists on the OTCQB.

BioVie states that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis because of hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering the Company’s new drug candidate BIV201.

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The Food and Drug Administration (FDA) has never approved any drug specifically for treating ascites. BIV201 is a continuous infusion of the peptide terlipressin, first undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in approximately 40 countries for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the United States.

In April 2017, BioVie announced that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 could begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites because of advanced liver cirrhosis.

Additionally, BioVie announced in April 2017 the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites due to advanced liver cirrhosis.

In December 2017, BioVie announced that the FDA granted Fast Track designation for BIV201 (continuous infusion terlipressin), its patented Orphan drug candidate. BIV201 is now undergoing evaluation for the treatment of refractory ascites due to liver cirrhosis in a mid-stage (Phase 2a) US clinical trial.

Last week, BioVie announced that FDA granted an Orphan Drug designation to BioVie for terlipressin for the treatment of hepatorenal syndrome (HRS). The Company earlier secured an Orphan Drug designation for terlipressin for treating ascites and is exploring additional Orphan designation opportunities. An Orphan Drug designation usually provides 7 years of market exclusivity to the company that is first to obtain FDA marketing approval for the drug for the designated rare disease or condition.

BioVie, Inc. (BIVI), closed Monday's trading session at $0.041, down 14.58%, on 30,000 volume with 3 trades. The average volume for the last 3 months is 62,734 and the stock's 52-week low/high is $0.012/$0.25.


ZIVO Bioscience, Inc. (ZIVO)

Equity Clock, OTC Markets, RedChip, Marketbeat, Street Insider, Business Insider, Wallet Investor, Pink Investing,, Zacks, Ceocast News, MarketWatch, Marketwired, and Stockhouse reported earlier on ZIVO Bioscience, Inc. (ZIVO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

ZIVO Bioscience, Inc.’s dedication is to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains. Additionally, the Company engages in the development of natural bioactive compounds for use as dietary supplements and food ingredients, and biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically centered on autoimmune and inflammatory response modulation.

ZIVO Bioscience has its head office in Keego Harbor, Michigan. Its wholly-owned subsidiary is WellMetris, LLC. ZIVO lists on the OTC Markets Group`s OTCQB.

ZIVO is a biotech/agtech R&D company involved in the commercialization of nutritional and medicinal products derived from proprietary algal strains. The Company is re-inventing itself as a licensor of internally developed intellectual property (IP), which includes its proprietary algae cultures, in addition to IP secured through strategic acquisitions.

ZIVO Bioscience works to totally harness the beneficial effects of its natural bioactive agents and make them affordable and readily available in a useful and convenient form. More recently, the Company has continued to concentrate almost exclusively on dairy cow applications for its proprietary algal biomass, extracts and any high-value bioactive compounds thereof. This is while developing the business case and production scale-up to cultivate and productize the algal biomass.

ZIVO’s core IP comprises the algae culture itself, the patented process of producing that culture, and the bioactive compounds or molecules that can be extracted, as well as the application of that culture or extract in supporting health maintenance and longevity. The Company’s plan is to approach the near-term markets first - animal applications, human food ingredients, and human dietary supplements.

Today, ZIVO Bioscience announced that Company principals executed a Letter of Intent (LOI) with Dr. Steven K. Grekin, an innovator and pioneer in dermatological practices centered on anti-aging and skin health. This LOI describes a joint effort to develop, test and launch an exclusive line of products, which feature ZIVO's proprietary algae strain that has recently been affirmed Generally Recognized As Safe (GRAS). This recent development permits ZIVO Bioscience to straightaway engage in product development and sales – in this instance, a line of nutritional products developed for Dr. Grekin.

ZIVO Bioscience, Inc. (ZIVO), closed Monday's trading session at $0.14762, down 1.03%, on 51,391 volume with 16 trades. The average volume for the last 3 months is 55,790 and the stock's 52-week low/high is $0.002/$0.189.


BioRestorative Therapies, Inc. (BRTX)

Simply Wall St, MarketWatch, Barchart, Stockopedia, ProActive Capital GuruFocus, Investor Ideas, Corporate Information, Streetwise Reports, Zacks, Stockhouse, Marketbeat, Capital Cube, Pink Investing, Proactive Investors, 4-Traders, Market Screener, and InvestorsHub reported earlier on BioRestorative Therapies, Inc. (BRTX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BioRestorative Therapies, Inc. is a life sciences company concentrating on adult stem cell-based therapies for diverse personal medical applications. The OTCQB-listed Company develops products and medical procedures utilizing cell and tissue protocols, chiefly involving adult stem cells. BioRestorative Therapies has its corporate, administrative, and laboratory operations in Melville, New York.

The Company’s goal is to become a leader in providing medical procedures using cell and tissue protocols, mainly involving adult stem cells (non-embryonic), and enabling patients to undergo minimally invasive cellular-based treatments. BioRestorative Therapies is developing a cell-based therapy to target obesity and metabolic disorders employing brown adipose (fat) derived stem cells to produce brown adipose tissue (BAT). The intention of BAT is to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.

The Company`s lead cell therapy candidate is BRTX-100. This product is formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. BioRestorative’s products and medical procedures include brtxDISC™ (Disc Implanted Stem Cells), its Disc/Spine Program, as well as ThermoStem®, its Metabolic Program.

brtxDISC™ is an investigational non-surgical treatment for bulging and herniated lumbar discs. brtxDISC™’s intention is for patients who have failed non-invasive procedures and face the prospect of surgery. ThermoStem® is a treatment utilizing brown fat stem cells. ThermoStem® is under development for metabolic disorders. This includes diabetes and obesity.

In addition, BioRestorative Therapies is the beneficiary of a patent granted for a licensed curved needle device (CND). The design of it is to deliver cells and/or other therapeutic products or material to a site having damage in need of facilitated repair.

In November, BioRestorative Therapies announced that the United States Patent and Trademark Office (USPTO) issued the Company a Notice of Allowance on its patent application related to a human brown adipose tissue differentiated cell that is part of its metabolic (ThermoStem®) program. Upon issuance in the U.S., the final patent will offer patent protection for a human brown adipose tissue differentiated cell derived from an isolated human brown adipose tissue stem cell.

This will be the fourth patent issued for BioRestorative Therapies` brown fat metabolic program. It follows a patent issued to BioRestorative in the U. S. in September 2015, Australia in April 2017, and Japan in December 2017.

BioRestorative Therapies, Inc. (BRTX), closed Monday's trading session at $0.77825, down 2.19%, on 60,328 volume with 42 trades. The average volume for the last 3 months is 97,884 and the stock's 52-week low/high is $0.625/$4.00.


The QualityStocks Company Corner

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (“POS”), e-commerce, and mobile devices, today announced that it won two categories at ACQ5 Global Awards 2018 and that its CEO Oleg Firer was named “Gamechanger of the Year”.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

With an eye on emerging markets, Net Element is pursuing growth opportunities and footholds in a number of industries. The company’s most recent application of its technology is to the cannabis industry, which is paced to hit $591 million and could increase 40 times in the next four years. This rampant growth also creates heightened need for smooth transactions between merchants and consumers. Payment processing and compliance for the cannabis industry has become increasingly complex, and Net Element’s Unified Payments subsidiary is addressing the challenges by offering a compliant, seamlessly integrated payment solution that makes it simple to transact.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $7.73, up 8.42%, on 186,015 volume with 1,055 trades. The average volume for the last 3 months is 287,009 and the stock's 52-week low/high is $3.665/$33.51.

Recent News


Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE:FRSX), an innovator in automotive vision systems, announced today that it has successfully delivered and installed its first QuadSight™ prototype system for evaluation by a leading European manufacturer of commercial vehicles. QuadSight™ was successfully installed on the manufacturer’s truck and passed all initial performance testing. The customer will continue independent evaluation of the system’s performance.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $2.4999, up 9.64%, on 110,580 volume with 244 trades. The average volume for the last 3 months is 16,598 and the stock's 52-week low/high is $2.009/$7.30.

Recent News


Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CHMJF).

CannabisNewsAudio announces the Audio Press Release (APR) titled “Change in Attorney General Could Mean a Cannabis Revolution in the US,” featuring Chemistree Technology, Inc. (CSE: CHM) (OTCQB: CHMJF). To hear the CannabisNewsAudio version, visit: To read the full editorial, visit:

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF) an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements’ expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company “maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S.”

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree’s working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed the day's trading session at $0.4113, up 11.89%, on 133,527 volume with 95 trades. The average volume for the last 3 months is 7,342 and the stock's 52-week low/high is $0.268/$0.7158.

Recent News


Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a biotech company and drug delivery platform innovator, announced in a recent press release ( that it has submitted a Health Canada research application and has appointed a new member to its executive team.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.18, up 3.28%, on 101,932 volume with 170 trades. The average volume for the last 3 months is 237,510 and the stock's 52-week low/high is $0.775/$2.54.

Recent News


Zenergy Brands, Inc. (ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

Zenergy Brands, Inc. (OTC: ZNGY), a company passionate about helping reduce carbon emissions across the nation, boasts the ability to lower its customers’ energy consumption by 20 to 60 percent. Its Zero Cost Program, offered to corporate clients, comes fully complete and ready to operate upon purchase. After their initial investment, clients have found the product to fully pay for itself within five to seven years due to the energy conservation savings.

Zenergy Brands, Inc. (ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.0001, even for the day, on 26,866,900 volume with 18 trades. The average volume for the last 3 months is 26,447,720 and the stock's 52-week low/high is $0.00009/$0.0189.

Recent News


QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) is capping an eventful year at its Irgon Lithium Mine Project by preparing to rapidly expand exploration and bring the project into production once its qualified engineer (SGS Canada) has upgraded the historical resource estimate to be compliant with current NI 43-101 standards.

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.2088, up 0.87%, on 38,649 volume with 23 trades. The average volume for the last 3 months is 98,259 and the stock's 52-week low/high is $0.168/$1.275.

Recent News


DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company, (“DPW” or “the Company”) reported its subsidiary, Coolisys Technologies, Inc. (“Coolisys”) has received two repeat customer contracts valued at $1.3 million.

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

  • The highest efficiency and highest density power converters and inverters
  • Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
  • Very high-frequency filters
  • Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

  • Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
  • Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
  • Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
  • Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
  • Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

  • Achieve compounded annual revenue growth of 25-35%
  • Achieve compounded annual net Income growth of 5%
  • Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.2217, off by 0.09%, on 1,104,279 volume with 2,967 trades. The average volume for the last 3 months is 1,240,474 and the stock's 52-week low/high is $0.219/$5.95.

Recent News


Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

NetworkNewsWire released a report today on Youngevity International, Inc. (NASDAQ: YGYI) examining how the opportunities in the direct selling market are enormous and the company is perfectly poised to exploit them. To view the full article, visit: Also today, NetworkNewsWire released a report on the company detailing the auspicious timing of the online availability of the company’s HempFX, hemp-derived cannabidiol products.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $6.80, up 0.29%, on 130,116 volume with 627 trades. The average volume for the last 3 months is 560,049 and the stock's 52-week low/high is $3.167/$16.25.

Recent News


Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures (OTC: NUGS), a cannabis industry incubator, is building its international portfolio of companies in the startup and growth stages as acceptance of cannabis continues to grow in both the U.S. and Canada. To view the full article, visit: Also today, CannabisNewsWire released a report highlighting the company which examines how cultivation by both large and small growers is powering growth across the cannabis industry.

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $1.73, off by 4.42%, on 61,117 volume with 130 trades. The average volume for the last 3 months is 51,630 and the stock's 52-week low/high is $0.052/$7.13.

Recent News


Plus Products Inc. (CSE: PLUS)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS).

Plus Products Inc. (CSE: PLUS), the leading cannabis edibles brand in California is pleased to announce that it has signed a definitive agreement (the “Definitive Agreement”) whereby PLUS™ intends to acquire the assets of California-based cannabis-infused baked goods brand GOOD CO-OP, INC. (“GOOD”) in an all share transaction.

Plus Products Inc. (CSE: PLUS) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLUS), closed the day's trading session at $5.49, off by 3.35%, on 60,886 volume with 64 trades. The average volume for the last 3 months is 194,186 and the stock's 52-week low/high is $3.51/$7.25.

Recent News


Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced recognition of its wholly owned subsidiary, 7ACRES, as the Brand of the Year at the 2018 Canadian Cannabis Awards presented by Lift & Co. (TSX.V: LIFT). To view the full press release, visit:

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.15, off by 4.96%, on 561,318 volume with 415 trades. The average volume for the last 3 months is 826,050 and the stock's 52-week low/high is $0.95/$2.79.

Recent News


Generation Alpha, Inc. (GNAL)

The QualityStocks Daily Newsletter would like to spotlight Generation Alpha, Inc. (GNAL).

CannabisNewsAudio announces the Audio Press Release (APR) titled “Cannabis Industry Stays in Spotlight with Ongoing Developments,” featuring Generation Alpha, Inc. (OTCQB: GNAL). To hear the CannabisNewsAudio version, visit: To read the full editorial, visit:

Generation Alpha, Inc. (GNAL) was established in 2010 as a vertically integrated technology innovator, developer, manufacturer and distributor focused on bringing products and solutions to both commercial and individual growers in the United States. Originally named Solis Tek Inc., the company changed its name to Generation Alpha in September 2018 and announced an increased focus on providing innovative and must-have cannabis products and services to a growing industry.

“Generation Alpha for us means ‘new beginning’” said Generation Alpha CEO Alan Lien, when the name change was announced. “It is the new wave of how people and brands connect. We are excited with the transformation of our business strategy, our progress at our Arizona facility and the additional growth opportunities our team has identified elsewhere in the cannabis industry. While we are pleased with our innovation and progress in our Solis Tek lighting and Zelda Horticulture divisions, we believe?Generation Alpha?represents our philosophy of bringing the best cannabis products and services to the market. We are confident that this shift in our business strategy will create long-term shareholder value through diversified segments in the legalized cannabis industry.”

The name change reflects the company’s strategy to leverage business opportunities in different legalized cannabis spaces, including cultivation, processing and retail facilities. As part of that focus, Generation Alpha acts as the holding entity for a collection of companies that bring products and solutions to legal retail and commercial cannabis growers while utilizing its expertise to offer safe, quality and consistent products through its cultivation, processing, and retail facilities as well as branded products in both the medical and recreational markets. Along with its strong focus on the burgeoning cannabis market, Generational Alpha remains committed to developing and providing innovative products and services in both Solis Tek Digital Lighting, its lighting division, and Zelda Horticulture, its agricultural products division.

As part of a key piece of its cannabis focus, Generation Alpha acquired a cannabis cultivation and processing facility in Phoenix, Arizona, which is scheduled to begin operation in 2019. Currently in the design and development stage, the 70,000-square-foot facility will be one of the most technologically advanced cultivation and processing facilities in Arizona, which is a hot bed of cannabis cultivation in North America. Generation Alpha management is confident about the growth and profitability this facility provides as an essential component of its forward-thinking cannabis strategy.

Additional components of this strategy include the company’s GrowPro Solutions, Inc., a nationwide cannabis cultivator and processor and a variety of Generation Alpha brands, which include the innovation, design and selling of cannabis?products such as flower, oils and accessories in the legal medical and recreational markets.

The company’s Zelda Horticulture division offers commercial-grade rolling tables, greenhouses, PH stabilizer and nutrient products, and other agricultural products for cultivators around the world. Zelda’s custom-design cultivation options means its clients can count on increased agricultural productivity and efficiency.

Generation Alpha’s Solis Tek Digital Lighting division offers an extensive line of lighting equipment and accessories, including digital ballasts, reflectors,?complete lighting systems, single- and double-ended digital lamps, controllers and other accessories.?Each product is designed to help retail and commercial growers maximize quality and achieve higher yields and maximize quality.?

Generation Alpha, Inc. (GNAL), closed the day's trading session at $0.679, off by 1.59%, on 23,295 volume with 387 trades. The average volume for the last 3 months is 67,636 and the stock's 52-week low/high is $0.40/$2.64.

Recent News


BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) is a biotechnology company focusing its efforts on immuno-oncology through the development of targeted, safe treatment options for cancer.  To view the full article, visit:

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.0808, off by 0.25%, on 13,200 volume with 2 trades. The average volume for the last 3 months is 18,073 and the stock's 52-week low/high is $0.068/$0.1387.

Recent News


American Premium Water Corp. (HIPH)

The QualityStocks Daily Newsletter would like to spotlight American Premium Water Corp. (HIPH).

American Premium Water Corporation (OTC: HIPH) announces that it has engaged Canadian law firm Aird & Berlis with the intention to begin the process to list on a Canadian stock exchange. The Company’s goal is to be listed in Canada by the end of the first half of 2019.

American Premium Water Corp. (HIPH), headquartered in Playa Vista, California, is a diversified holding company, manufacturer, distributor and marketer of branded consumer products. HIPH, the acronym for “Hi-Power of Hydro,” maintains a portfolio of subsidiaries catering to the health-conscious consumer and luxury fashion brand connoisseur. The company’s two main pillars focus on the development of health and beauty biotech, dedicated to unlocking the power of hydrogen and nanotechnologies. Paired with cannabidiol or “CBD” in a unique beverage, the technology is proving to be a significant health and wellness option for astute consumers.

Among the company’s holdings are:

  • LALPINA Hydro beverages mix hydrogen with nanotechnology into consumer beverages that combine the best of health, nutrition and fitness to deliver short and long-term therapeutic health benefits. LALPINA Hydro utilizes atomic molecular hydrogen, or diatomic hydrogen, which converts antioxidants in the body to H2O to further enhance hydration, which helps increase endurance, reduce lactic acid and melt away fatigue. Over 500 peer-reviewed articles demonstrate hydrogen to have therapeutic potential in essentially every organ of the human body and in 150 different human disease models.
  • LALPINA Hydro CBD is a technically superior CBD-infused beverage. Using hydro and nanotechnology, LALPINA Hydro CBD encapsulates water molecules with cannabidiol molecules, making them infinitely more bioavailable and accelerating delivery to the body’s cells and tissues. Each bottle of LALPINA Hydro CBD contains 3 million nanograms of CBD free from the psychoactive compound THC (tetrahydrocannabinol). HIPH is the first to introduce a hydro-nano CBD-infused beverage on the market, which is a more effective delivery mechanism for administering CBD into the blood stream than traditional beverages or oils, with up to a 90 percent higher absorption rates.

The company recently signed a distribution agreement for its subsidiary, LALPINA Hydro CBD, to sell its beverages to two SinglePoint, Inc. (OTCQB: SING) e-commerce channels: and SING is a technology and investment company with a portfolio that includes mobile payments, blockchain solutions and ancillary cannabis services. HIPH will drop ship its product to the customers.

HIPH CEO Ryan Fishoff said the e-commerce arrangements “could bring in excess of a million of revenue over the life of the agreement.” The agreement serves as a pillar of the company’s e-commerce distribution strategy, driving awareness and impressions for the LALPINA brand.

In addition, HIPH seeks to market emerging fashion brands and leverage its relationship with classic retail partners while incorporating disruptive blockchain technologies to expand its retail footprint with the following:

  • Gents, a producer of luxury hats and other fine accessories and apparel, was acquired in September 2017. Gents is distributed across many luxury retail outlets including Saks Fifth Avenue, Bloomingdales, Nordstrom, and other high-end channels. The company added the Worthy streetwear brand to its portfolio in June 2018.
  • HIPH also acquired the license to operate the FashionCoinX exchange, a blockchain exchange focused on creating utility tokens for the fashion industry, and created THRD Coin, a multi-branded utility rewards token that is also the first token to be traded on the exchange. The company is leveraging its retail footprint and expertise in the fashion and apparel space with the burgeoning blockchain sector.

American Premium Water Corp. (HIPH), closed the day's trading session at $0.028, off by 6.67%, on 12,736,312 volume with 478 trades. The average volume for the last 3 months is 19,074,944 and the stock's 52-week low/high is $0.0035/$0.1319.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.